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adenocarcinoma (AC) or squamous cell 
carcinoma (SCC) by standard histopath-
ologic methods.” In fact, adding a new 
diagnostic tool to the classical diagnostic 
tool might improve the diagnostic ability. 
Focusing on the use of microRNAassays, 
there are still left concern and questions 
on the cost effectiveness, availability, and 
complexity of the tests. These points have 
to be further discussed. Focusing on MiR-
205 MicroRNA, its diagnostic value for 
differentiating between AC and SCC is 
still controversial. Some previous reports 
showed limitation of its ability to diag-
nose SCC.2 Also, the MiR-205 can also 
increase in the case with severe inflam-
mation and benign tumor.3 The possibility 
of false-positive because of noncancerous 
lesion has to be further studied.
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In Response:
We thank Dr. Wiwanitkit for 
his comments on our study.1 The 
microRNA-based assay described in it 
requires the quantification of only four 
RNAs (miR-21, miR-205, and miR-375, 
and RNU6B). As already noted by us in 
the publication, this can be conveniently 
done in any laboratory with a quantita-
tive polymerase chain reaction machine, 
with time and material costs similar to 
those for immunohistochemistry-based 
diagnosis of non–small-cell lung can-
cer histology. However, the suitability 
of the assay for biospecimens with less 
than 90% tumor content has not been 
assessed by us. In our study, microdis-
section of tumor-containing regions of 
biopsied material was performed for 
76% of biopsies to have ≥90% tumor 
content in the specimens that were used 
for RNA extraction for the microRNA-
based assay.
The studies on the association 
of miR-205 with severe inflammation 
and benign tumor and the lack of a dif-
ferential expression of this microRNA 
between normal and tumor tissues, 
which Dr. Wiwanitkit refers to, con-
cern oral cancer and not cancer of the 
lung. In case of the latter, a significantly 
higher expression of miR-205 in lung 
squamous cell carcinoma tissue com-
pared with normal lung, or lung tissue 
with adenocarcinoma or benign dis-
eases has been noted by many2–5 and in 
Figure 1 of our article.1
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In Response:
We would like to thank Dr. Tapias 
and Dr. Lanuti for their comments on 
our recent article reporting on a mul-
ticenter cohort of 68 patients with 
solitary fibrous tumors of the pleura 
(SFTP), who were analyzed for the 
complete course of the disease in a 
routine practice setting.1 We acknowl-
edge that our recurrence rate of 30% 
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